Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome

PLoS One. 2015 Jul 21;10(7):e0133670. doi: 10.1371/journal.pone.0133670. eCollection 2015.

Abstract

Introduction: Squamous cell carcinoma (SCC), adenocarcinoma (AC), and adenosquamous carcinoma (ASC) are the most common histological subtypes of cervical cancer. Differences in the somatic mutation profiles of these subtypes have been suggested. We investigated the prevalence of somatic hot-spot mutations in three well-defined cohorts of SCC, AC, and ASC and determined the additional value of mutation profiling in predicting disease outcome relative to well-established prognostic parameters.

Materials and methods: Clinicopathological data were collected for 301 cervical tumors classified as SCC (n=166), AC (n=55), or ASC (n=80). Mass spectrometry was used to analyze 171 somatic hot-spot mutations in 13 relevant genes.

Results: In 103 (34%) tumors, 123 mutations were detected (36% in SCC, 38% in AC, and 28% in ASC), mostly in PIK3CA (20%) and KRAS (7%). PIK3CA mutations occurred more frequently in SCC than AC (25% vs. 11%, P=0.025), whereas KRAS mutations occurred more frequently in AC than SCC (24% vs. 3%, P<0.001) and ASC (24% vs. 3%, P<0.001). A positive mutation status correlated with worse disease-free survival (HR 1.57, P=0.043). In multivariate analysis, tumor diameter, parametrial infiltration, and lymph node metastasis, but not the presence of a somatic mutation, were independent predictors of survival.

Conclusion: Potentially targetable somatic mutations occurred in 34% of cervical tumors with different distributions among histological subtypes. Precise classification of cervical carcinomas in combination with mutation profiling is valuable for predicting disease outcome and may guide the development and selection of tumor-specific treatment approaches.

MeSH terms

  • Adenocarcinoma / classification
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / pathology
  • Adult
  • CARD Signaling Adaptor Proteins
  • Carcinoma, Squamous Cell / classification
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / pathology
  • Class I Phosphatidylinositol 3-Kinases
  • Cytoskeletal Proteins / genetics
  • Female
  • Humans
  • Middle Aged
  • Mutation*
  • Neoplasm Metastasis
  • Phosphatidylinositol 3-Kinases / genetics
  • Prognosis
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Uterine Cervical Neoplasms / classification
  • Uterine Cervical Neoplasms / genetics*
  • Uterine Cervical Neoplasms / pathology

Substances

  • CARD Signaling Adaptor Proteins
  • Cytoskeletal Proteins
  • KRAS protein, human
  • PYCARD protein, human
  • Phosphatidylinositol 3-Kinases
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CA protein, human
  • Proto-Oncogene Proteins p21(ras)

Grants and funding

The authors have no support or funding to report.